Agilect Could Launch In Mid-2005 After Teva Responds To “Approvable” Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Written response will trigger FDA’s six-month review clock, setting an estimated action date in May. Teva and Eisai plan to launch the Parkinson’s disease therapy within two months following approval.